Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Mindfulness and Cognitive Training in a CBT-resistant Patient With Gambling Disorder

A Combined Therapy to Enhance Self-control

von Hammerstein, Cora Master; Miranda, Ruben Master; Aubin, Henri-Jean MD, PhD; Romo, Lucia PhD; Khazaal, Yasser MD, PhD; Benyamina, Amine MD, PhD; Luquiens, Amandine MD, PhD

doi: 10.1097/ADM.0000000000000433
Case Reports
Buy

Despite the major health consequences of problem gambling, such as suicide, over-indebtedness, delinquency, or family problems, there is currently no approved drug available for the treatment of problem gambling. The efficacy of cognitive behavioral therapies (CBTs) has been demonstrated repeatedly. However, some people seem resistant to conventional CBT alone. We present the case of a 59-year-old woman with a gambling disorder, who relapsed, despite a CBT-based intervention, and who then received a combined therapy aiming to enhance self-control: a mindfulness-based therapy and cognitive training targeting inhibition.

Department of Psychiatry and Addictology, Paul Brousse Hospital, University Paris-Saclay, University Paris-Sud, UVSQ, CESP, INSERM U 1178, APHP Villejuif, France (CvH, RM, H-JA, AB, AL); EA 4430 CLIPSYD, University Paris Ouest Nanterre la Défense (CvH, LR); Inserm, U894, Center for psychiatry and neuroscience, 75014 Paris, France (LR); University of Geneva, Geneva, Switzerland (YK).

Send correspondence to Cora von Hammerstein, Master, Hopital Paul Brousse/Université Paris nanterre, villejuif, France. E-mail: hammersteincf@gmail.com.

Received 10 August, 2017

Accepted 21 May, 2018

HJA has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Lundbeck, Merck-Serono, Mundipharma, Novartis, and Pfizer. LR has received sponsorship to participate in scientific reaserch funded by PMU and FDJ through a convention with the University Paris Ouest Nanterre la Défense. AB has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Bristol-Myers-Squibb, Lundbeck, Merck-Serono and Mylan and is member of the invidor board. AL has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Lundbeck and Indivior. The other authors declare no conflicts of interest. All authors have seen and approved the final version of the manuscript being submitted. They warrant that the article is the authors’ original work, hasn’t received prior publication and isn’t under consideration for publication elsewhere.

© 2018 American Society of Addiction Medicine